There is currently only one drug that has demonstrated the potential to be a safe and effective treatment for COVID-19 in clinical trials: Gilead Sciences’ remdesivir. Today’s article, however, highlights a small, under-the-radar biotech with an experimental drug that has shown early promise in fighting COVID-19 when used in combination with remdesivir, reducing the replication of the novel coronavirus to “undetectable levels”. Could this biotech piggyback on Gilead’s success with remdesivir, creating a big opportunity for investors? CLICK HERE.
Remdesivir’s COVID-19 Success Could Create A Big “Piggyback” Opportunity For This Under-The-Radar Biotech
- by Bob Mitchell
Tags:Biotech InvestmentsBiotech StocksCOVID-19 SuccessInvestment OpportunityinvestorsNovel CoronavirusPiggyback OpportunityRemdesivir